In Vitro Mucosal Irritation Testing: Principles, Standards, Methods, and Applications

In vitro mucosal irritation testing is a biological safety evaluation method that assesses whether medical devices, biomaterials, cosmetics, or their extracts cause irritation to mucous membranes using human cell-based tissue models rather than live animals. Aligned with ISO 10993-23 and the 3Rs principle (Replacement, Reduction, Refinement), this testing approach is increasingly accepted by regulatory authorities worldwide for medical device registration and cosmetic safety assessment. This article provides a comprehensive technical overview of in vitro mucosal irritation testing, covering sample requirements, testing items, methodologies, applicable standards, and practical applications.

Technical Overview

In vitro mucosal irritation testing evaluates the potential of medical devices, materials, or their extracts to cause irritation to mucosal surfaces—including the oral cavity, vagina, rectum, eye (ocular mucosa), and urinary tract—without the use of animal models. It serves as a critical component of the biological evaluation of medical devices required by ISO 10993-1 and specifically addresses the irritation endpoint of biological safety assessment.

Historically, mucosal irritation was assessed through in vivo rabbit models, such as the vaginal or oral mucosal irritation tests described in ISO 10993-10. The publication of ISO 10993-23:2021 marked a significant paradigm shift, establishing a framework in which in vitro methods based on reconstructed human epithelium (RhE) models or other non-animal approaches are used as the first step in irritation testing. A comparable framework is reflected in the Chinese national standard GB/T 16886.23.

In vitro mucosal irritation testing is typically performed using three-dimensional tissue constructs cultured from human epithelial cells at an air-liquid interface. These tissues closely mimic the stratified squamous epithelium of natural mucosal barriers. Test substances or extracts are applied directly to the tissue surface, and quantitative endpoints—such as tissue viability, inflammatory mediator release, and barrier integrity—are measured to classify the material as an irritant or non-irritant.

• Supports the 3Rs principle by reducing and replacing animal use in safety testing
• Offers superior human biological relevance compared with animal models
• Delivers shorter turnaround times and lower overall testing costs
• Provides quantitative, reproducible endpoints suitable for regulatory submissions

Testing Samples

Medical Devices Contacting Mucosal Membranes

Devices classified under ISO 10993-1 as surface devices contacting intact mucosal membranes or external communicating devices with mucosal contact are primary candidates for this testing. Typical examples include:

• Urinary catheters, urethral stents, and bladder irrigation devices
• Endotracheal tubes, laryngeal masks, and nasal delivery devices
• Condoms, diaphragms, intrauterine devices, and vaginal rings
• Dentures, orthodontic appliances, dental impression materials, and filling materials
• Oral hygiene products, mouth rinses, and throat sprays
• Contact lens care solutions and ophthalmic drug delivery devices
• Gastrointestinal tubes and rectal delivery devices

Test Sample Preparation and Extracts

According to ISO 10993-12, test samples are prepared as extracts using both polar and non-polar solvents when the material composition is not fully characterized. Common extraction vehicles include 0.9% sodium chloride solution or serum-free culture medium (polar) and vegetable oils such as sesame oil (non-polar). Standard extraction ratios are typically 0.2 g/mL for materials between 0.5 mm and 1.0 mm in thickness, or surface-area-based ratios for thin films and membranes. Extraction conditions commonly include 37°C for 24 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected to maximize the release of leachable substances without degrading the material.

Cosmetics and Consumer Products

Mouthwashes, toothpastes, intimate hygiene products, ophthalmic formulations, and other products intended for direct mucosal contact can be evaluated directly or after dilution, depending on the intended use concentration and the applicability domain of the chosen in vitro method.

Chemicals and Pharmaceutical Formulations

Industrial chemicals subject to registration requirements, as well as pharmaceutical and biocidal formulations intended for mucosal administration, may also undergo in vitro mucosal or ocular irritation screening as part of their safety data packages.

Testing Items

In vitro mucosal irritation testing can be tailored to the anatomical site of intended device contact. Core testing items include:

• Oral mucosal irritation testing using reconstructed human oral epithelium models
• Vaginal mucosal irritation testing using reconstructed human vaginal-ectocervical epithelium models
• Rectal mucosal irritation testing
• Ocular (eye) irritation and serious eye damage testing using reconstructed human cornea-like epithelium models
• Bladder and urethral epithelium compatibility testing
• Intracutaneous reactivity assessment, frequently evaluated in parallel for extractable substances

Measured endpoints typically include tissue viability (MTT reduction), release of inflammatory mediators such as interleukin-1 alpha (IL-1α), interleukin-6 (IL-6), and interleukin-8 (IL-8), barrier integrity, and histomorphological examination of the tissue construct.

Testing Methods

Reconstructed Human Epithelium (RhE) Models

The most widely adopted in vitro approach uses commercially available three-dimensional RhE tissue constructs derived from human oral, vaginal, or corneal epithelial cells. Test articles, extracts, or liquids are applied topically to the tissue surface for a defined exposure period. Following exposure and post-incubation, tissue viability is quantified using the MTT assay, in which mitochondrial dehydrogenases of viable cells reduce the yellow tetrazolium salt to purple formazan crystals. The effective concentration reducing viability to 50% of control (IC50) or the exposure time reducing viability to 50% (ET50) is compared against classification thresholds to determine irritant potential.

Inflammatory Mediator Release Assays

Because sub-cytotoxic exposure may still trigger irritation responses, the release of pro-inflammatory cytokines such as IL-1α, IL-6, IL-8, and prostaglandin E2 into the culture medium is quantified using enzyme-linked immunosorbent assay (ELISA). Elevated cytokine levels relative to negative and positive controls provide a sensitive indicator of mucosal inflammatory potential.

Barrier Integrity Measurements

Barrier function can be assessed through transepithelial electrical resistance (TEER) measurement or fluorescent dye penetration assays. A marked decrease in TEER or increased dye permeability indicates disruption of epithelial barrier integrity, an early marker of irritant damage.

Standards and Reference Frameworks

• ISO 10993-23:2021 — Biological evaluation of medical devices, Part 23: Tests for irritation, which introduces the in vitro irritation testing strategy
• ISO 10993-10 — Biological evaluation of medical devices, Part 10: Tests for skin sensitization and irritation (in vivo reference methods)
• ISO 10993-12 — Biological evaluation of medical devices, Part 12: Sample preparation and reference materials
• GB/T 16886.23 — Chinese national standard equivalent covering in vitro irritation testing for medical devices
• OECD Test Guidelines 437, 438, 491, and 492 — recognized alternative methods for eye irritation and serious eye damage
• OECD Test Guideline 439 — in vitro skin irritation method, frequently adapted for mucosal screening

General Test Procedure

A typical testing workflow proceeds as follows: sample receipt and characterization, extract preparation or direct dosing solution preparation, topical application to the RhE tissue model, defined exposure and rinsing, post-treatment incubation, quantification of viability and inflammatory endpoints, and final data analysis with classification according to the applicable prediction model. Positive controls (such as SDS) and negative controls (vehicle or buffered solution) are included in every test run to confirm system responsiveness.

Applications

In vitro mucosal irritation testing supports a broad range of regulatory and product development objectives:

• Biological evaluation reports for medical device registration submissions in major markets, including China, the United States, and the European Union
• Compliance demonstrations for the European Medical Device Regulation (MDR) and associated biological safety documentation
• Safety substantiation for cosmetics and personal care products in jurisdictions where animal testing is restricted or prohibited
• Screening of candidate materials, coatings, and formulations during early-stage research and development
• Support for chemical registration programs requiring irritation and corrosivity endpoint data
• Quality control and change evaluation for established device materials and manufacturing processes

Accredited third-party laboratories routinely conduct these studies under quality management systems compliant with ISO/IEC 17025, generating data packages suitable for inclusion in regulatory dossiers.

FAQ

Why choose in vitro mucosal irritation testing over in vivo animal testing?

In vitro methods align with the 3Rs principle, use human-derived tissue models with greater biological relevance to patients, reduce ethical concerns associated with animal use, and are now recognized under ISO 10993-23 as the preferred first step in irritation assessment. They also typically offer shorter timelines and lower costs.

Which standard governs in vitro irritation testing for medical devices?

ISO 10993-23:2021 is the primary international standard, with GB/T 16886.23 serving as the corresponding Chinese national standard. Sample preparation follows ISO 10993-12, and the overall evaluation strategy is defined by ISO 10993-1.

What samples are required for testing?